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LKB1 in transmembrane receptor signaling
Imoh S. Okon and Ming-Hui Zou
Signal processing and integration is critical in 
physiology, as it is in disease conditions. Conversion of 
extracellular signals into appropriate biological responses 
by cell membrane receptors, and subsequent extinction 
of signaling events is critical to cellular hemostasis. 
Defective trafficking, internalization or degrardation of 
transmembrane receptors (TMRs) result in perturbed 
activation of signaling networks, which play essential 
roles in disease initiation or accentuation. In our recent 
study, we found that liver kinase B1 (LKB1), a calcium-
calmodulin family member abrogated neuropilin-1 (NRP-
1) protein in lung cancer clinical specimens and cell lines 
[1]. Surprisingly, this observation was reminiscent to our 
previous finding in which LKB1 attenuated the activation 
of a repertoire of receptor tyrosine kinases (RTKs), 
including EGFR, ErbB2, HGFR (c-Met) and EphA2 
[2]. The regulation of TMRs by LKB1 appears to be a 
recurring pattern in cancer cells but occur via different 
mechanisms. Unlike LKB1-mediated dephosphorylation 
of RTKs via accentuation of selected phosphatase activity, 
NRP-1 attenuation was promoted by LKB1-RAB7 
GTPase complex [1, 2]. We demonstrated for the first 
time that LKB1 is a RAB7 effector and suppresses tumor 
angiogenesis by promoting cellular trafficking of NRP-
1 from RAB7 vesicles to the lysosome for degradation. 
LKB1 specifically bound active GTP-Q67L RAB7 
construct, but not the dominant-negative GDP-T22N 
form. NRP-1 localization within RAB7, a late endocytic 
target was not detected in early (RAB5) or recycling 
(RAB11) endosomal markers [1]. With over 60 different 
mammalian RAB family-members, the selectivity may be 
context-dependent, and the relationship between LKB1 
and RAB family-members requires further investigation. 
Our findings indicated that hypoxia, a property of tumor 
micro-environment promotes LKB1 nuclear export to 
the cytosol, where it interacts with NRP-1 and RAB7 
[1]. LKB1 expression was consistent with its tumor 
suppression functions, which included inhibition of 
angiogenesis and tumor growth in vivo. Conversely, loss 
of LKB1 exacerbated tumor-enhancing phenotypes [1]. 
We have recently observed a similar inverse expression 
profile between LKB1 and NRP-1 proteins within 
endometrial cancer specimens. We found that NRP-
1 positively correlated with NEDD9 pro-metastatic 
protein. As expected, LKB1 abrogation of NRP-1 protein 
correlated with decreased metastatic potential of cancer 
cells in vitro (unpublished observations). 
In contrast to well-established RTKs, such as 
EGFR that have been studied for decades, several NRP-
1 functions remain relatively unknown. NRP-1 is a non-
tyrosine kinase, type-I transmembrane receptor that 
is largely associated with the VEGF receptor family. 
Canonical NRP-1 functions in tumor angiogenesis is 
strongly linked to VEGFR2. In our studies, NRP-1-
mediated tumor phenotypes were independent of VEGFR2 
in lung and endometrial cancer specimens [1]. Angiogenic-
switch which is characterized by heightened development 
of new blood vessels, serve to enhance nutrition and 
oxygen availability required for tumor progression, 
and NRP-1 may be critical to the process. LKB1, as a 
key regulator of TMRs influences receptor activation, 
trafficking, internalization, recycling and degradation. 
As expected, the attenuation of TMR-mediated signaling 
events impact biological and functional outcomes, such 
as tumor angiogenesis and migration. We have found 
decreased recycling potential in LKB1-positive cells 
relative to controls (LacZ) following ligand stimulation 
at different time intervals. We also observed that LKB1 
associates with another GTPase protein, dynamin2 
(unpublished observations), suggesting that LKB1 may 
possess TMR trafficking functions via selective complex 
formation with GTPase family members.
LKB1-mediated targeting of TMRs appear to 
be specific and highly selective. For example, NRP-2, 
an isoform of neuropilin receptors was unaffected by 
LKB1. Unlike NRP-1, NRP-2 protein was stable under 
varying conditions, including hypoxia. This observation 
is consistent with a recent report that described NRP-
1 attenuation under starvation compared with robust 
NRP-2 expression [3]. The reasons for these differences 
are unclear, however both receptors share only a 44% 
sequence homology which may account for differential 
regulation with respect to LKB1. These differences may 
also explain divergent functions in development and 
disease. Although both are important in the vascular 
system, NRP-1 is widely linked with tumor angiogenesis 
while NRP-2 is associated with lymphangiogenesis 
[4]. Interestingly, LKB1 failed to abrogate TMRs at the 
message level, suggesting posttranslational modifications 
which may include, acetylation, phosphorylation or 
farnesylation. LKB1 possesses a farnesylation site 
at the C-terminal domain, and potential functions of 
the domain remains to be explored. At the last count, 
LKB1 modulatory functions involved approximately 
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13 downstream substrates, including the well-described 
energy sensor, AMP-activated protein kinase (AMPK). 
Such orchestrated regulation by LKB1 may directly 
modulate several signaling networks or occur indirectly 
via these substrates. Although several roles have been 
ascribed to LKB1 in the last decade, ranging from 
hematopoietic stem cell survival, tumor suppressor and 
cardiovascular functions [1, 5-7], it appears that the 
ubiquitously expressed LKB1 gene has yet to play more 
critical roles in disease and physiology.  
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